TrialJournal of neuro-oncology2012

A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression.

Warren P Mason et al.PubMed ↗Publisher ↗

No numbers read from the abstract.